At the news
? NEUTRALIMPACT 2/10 8-K filed Nov 2, 2026 at 16:05 ET
10x Genomics appointed Ansuman Satpathy, a Stanford professor and venture partner, and Joseph Gilliam, President/COO of Glaukos Corporation, to its Board of Directors as Class III directors effective October 28, 2026. Gilliam was also appointed Chair of the Audit Committee. This is a routine board expansion with no departure of existing officers.
- Ansuman Satpathy and Joseph Gilliam appointed to the Board of Directors as Class III directors effective October 28, 2026.
- Satpathy is an Associate Professor at Stanford and a venture partner at Wing Venture Capital; Gilliam is President/COO of Glaukos Corporation.
- Joseph Gilliam appointed Chair of the Audit Committee on October 30, 2026, with an additional annual retainer of $25,000.
- Each new director receives standard non-employee director compensation: $60,000 annual cash retainer, a one-time RSU grant of $400,000, and annual RSU grants of $215,000.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access